Treating HIV during pregnancy: an update on safety issues.
about
Haematological safety of perinatal zidovudine in pregnant HIV-1-infected women in Thailand: secondary analysis of a randomized trialTransplacental exposure to AZT induces adverse neurochemical and behavioral effects in a mouse model: protection by L-acetylcarnitine.In utero exposure of female CD-1 Mice to AZT and/or 3TC: I. Persistence of microscopic lesions in cardiac tissue.Role of placental ATP-binding cassette (ABC) transporters in antiretroviral therapy during pregnancy.Zidovudine and Lamivudine for HIV Infection.Protective effect of pregnancy in rural South Africa: questioning the concept of "indirect cause" of maternal deathCongenital anomalies and in utero antiretroviral exposure in human immunodeficiency virus-exposed uninfected infantsIn utero exposure of female CD-1 mice to AZT and/or 3TC: II. Persistence of functional alterations in cardiac tissue.Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1.WR1065 mitigates AZT-ddI-induced mutagenesis and inhibits viral replication.Pregnancy outcomes in women with advanced HIV infection in Italy.Antiretroviral exposure during pregnancy and adverse outcomes in HIV-exposed uninfected infants and children using a trigger-based design.Pharmacokinetics and therapeutic drug monitoring of antiretrovirals in pregnant womenShort communication: High prevalence of vitamin D deficiency in HIV-infected and HIV-uninfected pregnant women.Considerations for the antiretroviral management of women in 2008.Pregnancy among HIV-infected refugees in Rhode Island.Effects of in utero antiretroviral exposure on mitochondrial DNA levels, mitochondrial function and oxidative stress.Molecular analysis of mitochondrial compromise in rodent cardiomyocytes exposed long term to nucleoside reverse transcriptase inhibitors (NRTIs).Vitamin D Deficiency in HIV Infection: Not Only a Bone Disorder.Perinatal exposure to antiretroviral therapy is associated with increased blood mitochondrial DNA levels and decreased mitochondrial gene expression in infants.Adverse effects of antiretrovirals in HIV-infected pregnant women.
P2860
Q28469195-18F2985C-BE3F-4D83-BFB0-8C6DA27D6F06Q28486041-490B6BFA-EBCF-4DC6-B47F-7FD1CCBDD080Q33839401-19458734-905F-424A-9AF5-801724E84B4EQ33954823-6A5BFFA9-2A17-4C17-BB66-D9B996A9B749Q34194561-83A1BB29-333D-4E57-875A-6EEDDFCFB43BQ34723368-3E488E86-4EA3-4BAC-A0F3-D00841FA2F75Q34860149-13775C4A-EE84-4F7B-AA6D-325E5E603F71Q35296291-75536616-4C21-49C2-93EC-04FA345A251EQ35327135-AD908842-00F3-4084-B045-41E41802E2E9Q35394336-C2E594B9-3309-4DDB-828B-0F566F0A1376Q35445035-D6A76AB9-B9B0-4860-8CA9-073C2F0E68D5Q36438846-6DF70DBC-0B37-44B0-813E-ABEFF20DF3D4Q36803454-B6BF644B-BCBD-4667-9922-6144FAD699DFQ37111446-E749D8B9-8EF4-4836-B52E-96F8BB2EC9FDQ37346125-4F15324E-F8E0-449B-99A3-C2B2726455F5Q37396905-D5EB9CEF-02CC-4D00-8CA4-C2F7663B6052Q37552456-56AAA13E-C8B8-456C-9085-31C77C473AB8Q39428374-7FB693F2-507F-40A6-9904-E22438910551Q40519915-7C2F8328-75C7-4B35-8533-8A921AA19923Q44097186-C0F31642-4F71-47BD-9375-70254E13E17FQ44301984-CF7B46C7-9EAE-4D7C-91BA-2DF8ED6E3B2C
P2860
Treating HIV during pregnancy: an update on safety issues.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Treating HIV during pregnancy: an update on safety issues.
@ast
Treating HIV during pregnancy: an update on safety issues.
@en
type
label
Treating HIV during pregnancy: an update on safety issues.
@ast
Treating HIV during pregnancy: an update on safety issues.
@en
prefLabel
Treating HIV during pregnancy: an update on safety issues.
@ast
Treating HIV during pregnancy: an update on safety issues.
@en
P2860
P1433
P1476
Treating HIV during pregnancy: an update on safety issues.
@en
P2093
D Heather Watts
P2860
P304
P356
10.2165/00002018-200629060-00002
P577
2006-01-01T00:00:00Z
P6179
1035620409